Day: June 18, 2025

Company announcement – No. 15 / 2025 Zealand Pharma announces positive topline results from 28-week Phase 1b trial with GLP-1/GLP-2 receptor dual agonist dapiglutideBody weight reductions of a mean of 11.6% after 28 weeks with dapiglutide escalated up to 26 mg, with 95% of trial participants being male, a median baseline BMI of 28.5 kg/m2, and no lifestyle modifications Treatment with dapiglutide was assessed to be safe and well-tolerated with gastrointestinal adverse events consistent with the profile reported with other incretin-based therapies Unique, dual mechanism, including GLP-2 activity, designed to target obesity-related comorbid conditions driven by low-grade inflammationCopenhagen, Denmark, June 18, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development...

NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia , June 18, 2025 (GLOBE NEWSWIRE) — GoldHaven Resources Corp. (“GoldHaven” or the “Company“) (CSE: GOH) (OTCQB: GHVNF) (FSE: 4QS), a Canadian resource sector exploration and development company is pleased to announce that it intends to conduct a non-brokered private placement of up to 3,846,154 flow-through shares (each an “FT Share”) at a price of $0.13 per FT Share for gross proceeds of up to $500,000 (the “Offering”). The FT Shares will be “flow through shares” as defined in subsection 66(15) of the Income Tax Act (Canada) (the “Tax Act”). All securities issued in connection with the Offering will be subject to a statutory hold period of four months and one day. The Company may pay finder’s fees...

RIBER reaffirms its strategic roadmap at the Annual General Meeting held on June 18, 2025 Bezons, June 18, 2025 – 5:45 PM – RIBER, a global market leader for molecular beam epitaxy (MBE) equipment for the semiconductor industry, held its Annual General Meeting today, chaired by Mrs. Annie Geoffroy, Chairwoman of the Company’s Board of Directors. All of the resolutions submitted to the vote were approved, including:The approval of the statutory and consolidated financial statements for the 2024 financial year. The appropriation of 2024 earnings and the distribution of a cash payout based on reimbursing part of the issue premium for €0.08 per share. The ex-dividend date will be June 23, 2025, followed by payment on June 25, 2025. The approval of the Statutory Auditors’ special report on related-party agreements. The authorizations...

PRESS RELEASE Paris – June 18, 2025 Bureau Veritas accelerates its LEAP | 28 strategy execution and evolves its Executive Committee Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC) is accelerating the execution of its LEAP | 28 strategy to reach its vision of being the preferred partner for its customers’ excellence and sustainability. Taking LEAP | 28 to the next level, Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment, strengthening its geographical platform with scalable Product Line structures, and optimizing its operations to enhance agility and effectiveness. Since the strategy launch in March 2024, LEAP | 28 strategy execution has progressed steadily in all three pillars – Portfolio, Performance & People – and is now reaching...

Dubai and Kyiv, June 18, 2025 – VEON Ltd. (Nasdaq: VEON), a global digital operator (“VEON” or the “Company”), today announces that Kyivstar, its digital operator in Ukraine, has received regulatory approval to conduct testing of Starlink Direct-to-Cell (D2C) services from the Ukrainian National Commission for the State Regulation of Electronic Communications, Radio Frequency Spectrum and the Provision of Postal Services (NCEC). Today’s regulatory approval for field testing follows successful integration of Kyivstar’s core mobile network with Starlink’s Direct-to-Cell service. Successful testing on the integration of Kyivstar’s SIM card with Starlink’s satellite network was recently completed at a partner technology evaluation lab in the United States. The success of the tests confirmed that Kyivstar SIM cards are compatible with the Starlink...

Series RIKB 28 1115 RIKB 38 0215ISIN IS0000028249 IS0000037265Maturity Date 11/15/2028 02/15/2038Auction Date 06/20/2025 06/20/2025Settlement Date 06/25/2025 06/25/202510% addition 06/24/2025 06/24/2025On the Auction Date, between 10:30 am and 11:00 am, the Government Debt Management will auction Treasury bonds in the Series, with the ISIN numbers and with the Maturity Dates according to the table above. Payments for the Treasury bonds must be received by the Central Bank before 14:00 on the Settlement Date, and the Bonds will be delivered in electronic form on the same day. Article 6 of the General Terms of Auction for Treasury bonds applies for the right to purchase an additional 10%. Further reference is made to the description of the Treasury bond and the General Terms of Auction for Treasury bonds on the Government...

SOGECLAIRBusiness corporation with a capital of 3 204 901 EurosHead Office: 7 avenue Albert Durand – 31700 BLAGNAC (France)Tel.: +33 (0)5.61.71.71.71 – www.sogeclair.com335 218 269 R.C.S. TOULOUSEInformation concerning the total number of voting rights and shares in the share capitalSection L.233-8 II of French commercial law (“Code de commerce”) and section 223-16 of the general rules of the French Financial Markets Authority (“Règlement général de l’Autorité des Marchés Financiers”)DATE Total number of shares in the share capital Total number of voting rights31 May 2025 3,204,901 Total voting rights – brut: 5,427,950    Total voting rights – net*: 5,278,647* net total:         total number of voting rights attached to the total number of shares – shares deprived of voting rights (treasury stock etc.)         ...

Updated key information relating to the share consolidation:  Date on which the terms and conditions of the share consolidation was made public: 11 April 2025; Share consolidation ratio: 100 old shares give 1 new share; Last day including right: 3 July 2025; Ex-date: 4 July 2025; Record date: 7 July 2025; and Date of approval: 11 April 2025 In connection with the share consolidation, the Company’s shares will be transferred to a new ISIN. Please find below the updated key information for the change of ISIN: Issuer: IDEX Biometrics ASA Old ISIN: NO0013107490 New ISIN: NO0013536078 Date of ISIN change: 4 July 2025. Rounding rules: If the share consolidation (reverse split) does not result in whole shares (fractional shares), the Board has in place an authorization from the 11 April 2025 Extraordinary General Meeting in the Company...

Reference is made to the stock exchange notices from IDEX Biometrics ASA (the “Company”) on 11 April and 6 June 2025 regarding the share consolidation and change of ISIN as resolved by the 11 April 2025 Extraordinary General Meeting in the Company (the “EGM”). Certain equity issues in IDEX, as previously announced, remain ongoing, and the effective date of the share consolidation will therefore be 4 July 2025, allowing completion of such equity issues prior to the effectiveness of the share consolidation.  For further information, please contact: Kristian Flaten, CFO, Tel: +47 95092322 E-mail: ir@idexbiometrics.com About IDEX Biometrics: IDEX Biometrics ASA (IDEX) is a global technology leader in fingerprint biometrics, offering authentication solutions across payments, access control, and digital identity. Our...

Over-Allotment Option Exercised in Full THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, June 18, 2025 (GLOBE NEWSWIRE) — Xtract One Technologies Inc. (TSX: XTRA) (OTCQX: XTRAF) (FRA: 0PL) (“Xtract One” or the “Company”) announces that it has closed its previously announced “bought deal” public offering (the “Offering”) conducted by Ventum Capital Markets (the “Underwriter”). Pursuant to the Offering, the Company issued an aggregate of 20,700,000 units (the “Units”) at a price of $0.39 per Unit for aggregate gross proceeds of $8,073,000, which includes the full exercise of the over-allotment option granted to the Underwriter. Each Unit consists of one common share of the Company (each, a “Common...